Advertisement
Orthocell Limited

Orthocell Limited (OCC.AX) Stock Competitors & Peer Comparison

See (OCC.AX) competitors and their performances in Stock Market.

OCC.AXASX
HealthcareBiotechnology
$0.74
$0.04(5.13%)
Australian Market is Open · 14:58
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
OCC.AXA$0.78+2.63%173.2M-15.60-A$0.05N/A
CSL.AXA$97.91+5.75%46.9B11.38A$8.60+4.35%
TLX.AXA$13.31+3.26%4.5B-443.67-A$0.03N/A
MSB.AXA$2.05+1.49%2.7B-20.50-A$0.10N/A
NEU.AXA$13.65+0.89%1.7B59.35A$0.23N/A
CU6.AXA$2.25-2.60%839.2M-8.04-A$0.28N/A
OPT.AXA$0.60+0.00%820.8M-1.40-A$0.43N/A
PYC.AXA$1.24-2.36%720.1M-15.44-A$0.08N/A
RAC.AXA$2.70-2.17%526.6M-54.00-A$0.05N/A
CUV.AXA$9.13+2.24%460.3M14.27A$0.64+0.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

OCC.AX vs CSL.AX Comparison June 2026

OCC.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OCC.AX stands at 173.2M. In comparison, CSL.AX has a market cap of 46.9B. Regarding current trading prices, OCC.AX is priced at A$0.78, while CSL.AX trades at A$97.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OCC.AX currently has a P/E ratio of -15.60, whereas CSL.AX's P/E ratio is 11.38. In terms of profitability, OCC.AX's ROE is -0.45%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, OCC.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for OCC.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions